Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Aug 8, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a method called the Erector Spinae Plane Block (ESPB) to see if it can help reduce chronic pain that some breast cancer patients experience after surgery, specifically mastectomy. Chronic postsurgical pain (CPSP) affects many patients, causing discomfort that can last long after surgery and impact their quality of life. The trial is testing whether combining ESPB with a medication called dexmedetomidine can lower the chances of developing this persistent pain after surgery.

To be eligible for the trial, participants must be between 18 and 84 years old and scheduled for a mastectomy due to breast cancer. They should not have had previous breast surgery or be dependent on strong pain medications. Participants in the trial can expect to receive either the ESPB treatment or standard care during their surgery and will be monitored to see how well they respond to the pain management approach. This study is important because it aims to find better ways to manage pain after breast cancer surgery and improve overall patient recovery and quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age of 18 years or over, but less than 85 years;
• • 2. Scheduled to undergo mastectomy for primary unilateral breast cancer.
• Exclusion Criteria:
• • 1. Previous breast cancer surgery with an incision of \>2 cm;
• • 2. Chronic opioid dependence or long-term intake of analgesic medicines (\>3 months);
• • 3. Any contraindication to erector spinae plane block, including intrathoracic infection, infection at the puncture site, cancer invasion of the puncture site, severe spinal deformity, history of spinal surgery, and severe coagulopathy;
• • 4. Inability to communicate in the preoperative period because of profound dementia, deafness, language barriers, or end-stage disease;
• • 5. History of malignant tumor in other organs, or a current combination of malignant tumor of other organs;
• • 6. History of coronary heart disease (diagnosed coronary stenosis, previous myocardial infarction, previous percutaneous coronary intervention or coronary artery bypass grafting); preoperative hepatic or renal impairment (alanine transaminase and/or aspartate transaminase ≥2 times of upper limit of normal, or serum creatinine\>133 µmol/L); history of peptic ulcer or hemorrhage; ASA classification IV or above;
• • 7. Allergy to ropivacaine.